PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
167.02
P/E exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 4.19. Michael Burry would check for market euphoria. Scrutinize growth expectations.
507.10
P/S exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 9.88. Jim Chanos would check for potential multiple compression risks.
11.11
P/B exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.39. Jim Chanos would check for potential asset write-down risks.
-141.08
Negative FCF while Drug Manufacturers - Specialty & Generic median P/FCF is 0.00. Seth Klarman would investigate cash flow improvement potential.
1005.18
P/OCF of 1005.18 versus zero operating cash flow in Drug Manufacturers - Specialty & Generic. Walter Schloss would verify operational quality.
11.11
Fair value ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.39. Jim Chanos would check for valuation bubble risks.
0.15%
Earnings yield 75-90% of Drug Manufacturers - Specialty & Generic median of 0.19%. John Neff would demand superior growth to justify lower yield.
-0.71%
Negative FCF while Drug Manufacturers - Specialty & Generic median yield is 0.00%. Seth Klarman would investigate cash flow improvement potential.